Centene (CNC) Stock Forecast & Price Target

Compare

2,442 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CNC Analyst Ratings

Moderate Buy

7 Buy

8 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Centene

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CNC Stock 12 Month Forecast

Average Price Target

$63.08

▲(89.37%Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Centene in the last 3 months. The average price target is $63.08 with a high forecast of $86.00 and a low forecast of $45.00. The average price target represents a 89.37% change from the last price of $33.31.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"44":"$44","87":"$87","54.75":"$54.8","65.5":"$65.5","76.25":"$76.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$86.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":63.08,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$63.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$45.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[44,54.75,65.5,76.25,87],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.65,58.90769230769231,61.16538461538461,63.42307692307692,65.68076923076923,67.93846153846154,70.19615384615385,72.45384615384616,74.71153846153845,76.96923076923076,79.22692307692307,81.48461538461538,83.74230769230769,{"y":86,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.65,57.144615384615385,57.63923076923077,58.13384615384615,58.628461538461536,59.12307692307692,59.61769230769231,60.11230769230769,60.606923076923074,61.10153846153846,61.59615384615385,62.090769230769226,62.58538461538461,{"y":63.08,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.65,55.753846153846155,54.857692307692304,53.96153846153846,53.065384615384616,52.169230769230765,51.27307692307692,50.37692307692308,49.480769230769226,48.58461538461538,47.68846153846154,46.79230769230769,45.896153846153844,{"y":45,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":65.34,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.91,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.83,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.94,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.52,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.06,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.58,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.03,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.16,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.45,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.41,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$86.00

Average Price Target$63.08

Lowest Price Target$45.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$37

Buy

11.08%

Upside

Reiterated

07/03/25

Centene's strong financial performance and undervaluation are significant positives. However, the bearish technical indicators and challenges highlighted in the earnings call, such as increased medical expenses, weigh on the overall score.

David WindleyJefferies

Jefferies

$61→$47

Hold

41.10%

Upside

Reiterated

07/02/25

Centene (CNC) Gets a Hold from Jefferies

A.J. RiceUBS

UBS

$80→$45

Hold

35.09%

Upside

Downgraded

07/02/25

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (NASDAQ: LQDA) and Centene (NYSE: CNC)

Sarah JamesCantor Fitzgerald

Cantor Fitzgerald

$90→$65

Buy

95.14%

Upside

Reiterated

07/02/25

Centene price target lowered to $65 from $90 at Cantor FitzgeraldCentene price target lowered to $65 from $90 at Cantor Fitzgerald

Justin LakeWolfe Research

Wolfe Research

―

Hold

―

Reiterated

07/02/25

Wolfe not a buyer of Centene on weakness given 2026 uncertaintyWolfe not a buyer of Centene on weakness given 2026 uncertainty

John StanselJ.P. Morgan

J.P. Morgan

$75→$48

Hold

44.10%

Upside

Assigned

07/02/25

Centene's Financial Outlook: Hold Rating Amid Revenue Headwinds and Regulatory Uncertainties

Joanna GajukBank of America Securities

Bank of America Securities

$65→$52

Hold

56.11%

Upside

Reiterated

07/02/25

Centene's Financial Outlook Challenged by Marketplace and Medicaid Trends, Hold Rating Issued

Lance WilkesBernstein

Bernstein

$86

Buy

158.18%

Upside

Assigned

07/02/25

Centene (CNC) Gets a Buy from Bernstein

Jason CassorlaGuggenheim

Guggenheim

―

Hold

―

Reiterated

07/02/25

Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (NASDAQ: VERA), Apogee Therapeutics (NASDAQ: APGE) and Centene (NYSE: CNC)

Andrew Mok CFABarclays

Barclays

$65→$45

Hold

35.09%

Upside

Reiterated

07/02/25

Barclays Remains a Hold on Centene (CNC)

Ryan LangstonTD Cowen

TD Cowen

$73

Buy

119.15%

Upside

Reiterated

07/02/25

Analysts Are Bullish on Top Healthcare Stocks: Centene (CNC), Cybin (CYBN)

Jailendra SinghTruist Financial

Truist Financial

―

Buy

―

Reiterated

07/02/25

Truist Financial Reaffirms Their Buy Rating on Centene (CNC)

Erin WrightMorgan Stanley

Morgan Stanley

$70

Buy

110.15%

Upside

Reiterated

07/01/25

Analysts Are Bullish on These Healthcare Stocks: Kymera Therapeutics (KYMR), Nektar Therapeutics (NKTR)

Stephen BaxterWells Fargo

Wells Fargo

$72

Buy

116.15%

Upside

Reiterated

07/01/25

Wells Fargo Reaffirms Their Buy Rating on Centene (CNC)

Michael WiederhornOppenheimer

Oppenheimer

$85

Buy

155.18%

Upside

Reiterated

04/28/25

Oppenheimer Sticks to Its Buy Rating for Centene (CNC)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$37

Buy

11.08%

Upside

Reiterated

07/03/25

David WindleyJefferies

Jefferies

$61→$47

Hold

41.10%

Upside

Reiterated

07/02/25

Centene (CNC) Gets a Hold from Jefferies

A.J. RiceUBS

UBS

$80→$45

Hold

35.09%

Upside

Downgraded

07/02/25

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (NASDAQ: LQDA) and Centene (NYSE: CNC)

Sarah JamesCantor Fitzgerald

Cantor Fitzgerald

$90→$65

Buy

95.14%

Upside

Reiterated

07/02/25

Centene price target lowered to $65 from $90 at Cantor FitzgeraldCentene price target lowered to $65 from $90 at Cantor Fitzgerald

Justin LakeWolfe Research

Wolfe Research

―

Hold

―

Reiterated

07/02/25

Wolfe not a buyer of Centene on weakness given 2026 uncertaintyWolfe not a buyer of Centene on weakness given 2026 uncertainty

John StanselJ.P. Morgan

J.P. Morgan

$75→$48

Hold

44.10%

Upside

Assigned

07/02/25

Centene's Financial Outlook: Hold Rating Amid Revenue Headwinds and Regulatory Uncertainties

Joanna GajukBank of America Securities

Bank of America Securities

$65→$52

Hold

56.11%

Upside

Reiterated

07/02/25

Centene's Financial Outlook Challenged by Marketplace and Medicaid Trends, Hold Rating Issued

Lance WilkesBernstein

Bernstein

$86

Buy

158.18%

Upside

Assigned

07/02/25

Centene (CNC) Gets a Buy from Bernstein

Jason CassorlaGuggenheim

Guggenheim

―

Hold

―

Reiterated

07/02/25

Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (NASDAQ: VERA), Apogee Therapeutics (NASDAQ: APGE) and Centene (NYSE: CNC)

Andrew Mok CFABarclays

Barclays

$65→$45

Hold

35.09%

Upside

Reiterated

07/02/25

Barclays Remains a Hold on Centene (CNC)

Ryan LangstonTD Cowen

TD Cowen

$73

Buy

119.15%

Upside

Reiterated

07/02/25

Analysts Are Bullish on Top Healthcare Stocks: Centene (CNC), Cybin (CYBN)

Jailendra SinghTruist Financial

Truist Financial

―

Buy

―

Reiterated

07/02/25

Truist Financial Reaffirms Their Buy Rating on Centene (CNC)

Erin WrightMorgan Stanley

Morgan Stanley

$70

Buy

110.15%

Upside

Reiterated

07/01/25

Analysts Are Bullish on These Healthcare Stocks: Kymera Therapeutics (KYMR), Nektar Therapeutics (NKTR)

Stephen BaxterWells Fargo

Wells Fargo

$72

Buy

116.15%

Upside

Reiterated

07/01/25

Wells Fargo Reaffirms Their Buy Rating on Centene (CNC)

Michael WiederhornOppenheimer

Oppenheimer

$85

Buy

155.18%

Upside

Reiterated

04/28/25

Oppenheimer Sticks to Its Buy Rating for Centene (CNC)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Centene

1 Month

xxx

Success Rate

20/32 ratings generated profit

Average Return

+1.24%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +1.24% per trade.

3 Months

xxx

Success Rate

35/52 ratings generated profit

Average Return

+3.60%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 67.31% of your transactions generating a profit, with an average return of +3.60% per trade.

1 Year

Michael WiederhornOppenheimer

Success Rate

29/52 ratings generated profit

Average Return

+8.87%

reiterated a buy rating 2 months ago

Copying Michael Wiederhorn's trades and holding each position for 1 Year would result in 55.77% of your transactions generating a profit, with an average return of +8.87% per trade.

2 Years

xxx

Success Rate

18/32 ratings generated profit

Average Return

+0.82%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 56.25% of your transactions generating a profit, with an average return of +0.82% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CNC Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CNC has received 17 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. CNC average Analyst price target in the past 3 months is 63.08.

Each month's total comprises the sum of three months' worth of ratings.

CNC Financial Forecast

CNC Earnings Forecast

Next quarter’s earnings estimate for CNC is $2.01 with a range of $1.60 to $2.20. The previous quarter’s EPS was $2.90. CNC beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 43.18% of the time in the same period. In the last calendar year CNC has Preformed in-line its overall industry.

CNC Sales Forecast

Next quarter’s sales forecast for CNC is $44.40B with a range of $42.96B to $46.30B. The previous quarter’s sales results were $46.62B. CNC beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 57.81% of the time in the same period. In the last calendar year CNC has Preformed in-line its overall industry.

CNC Stock Forecast FAQ

What is CNC’s average 12-month price target, according to analysts?

Based on analyst ratings, Centene’s 12-month average price target is 63.08.

What is CNC’s upside potential, based on the analysts’ average price target?

Centene has 89.37% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CNC a Buy, Sell or Hold?

Centene has a consensus rating of Moderate Buy which is based on 7 buy ratings, 8 hold ratings and 0 sell ratings.

What is Centene’s price target?

The average price target for Centene is 63.08. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $86.00 ,the lowest forecast is $45.00. The average price target represents 89.37% Increase from the current price of $33.31.

What do analysts say about Centene?

Centene’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of CNC?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Centene (CNC) Stock Forecast & Price Target

CNC Analyst Ratings

CNC Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Centene

CNC Analyst Recommendation Trends

CNC Financial Forecast

CNC Earnings Forecast

CNC Sales Forecast

CNC Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts